Skip to main content
Log in

Treatment-resistant depression associated with "disproportionate" costs in the USA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. funded by Janssen Scientific Affairs

Reference

  • Zhdanava M, et al. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. Journal of Clinical Psychiatry 82: No. 2, 16 Mar 2021. Available from: URL: http://doi.org/10.4088/JCP.20m13699

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Treatment-resistant depression associated with "disproportionate" costs in the USA. PharmacoEcon Outcomes News 879, 30 (2021). https://doi.org/10.1007/s40274-021-7753-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7753-5

Navigation